These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 12368392

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CYP17 genotype modifies the association between lignan supply and premenopausal breast cancer risk in humans.
    Piller R, Verla-Tebit E, Wang-Gohrke S, Linseisen J, Chang-Claude J.
    J Nutr; 2006 Jun; 136(6):1596-603. PubMed ID: 16702327
    [Abstract] [Full Text] [Related]

  • 3. Dietary lignan intakes and risk of pre- and postmenopausal breast cancer.
    McCann SE, Muti P, Vito D, Edge SB, Trevisan M, Freudenheim JL.
    Int J Cancer; 2004 Sep 01; 111(3):440-3. PubMed ID: 15221974
    [Abstract] [Full Text] [Related]

  • 4. Dietary lignan intake and postmenopausal breast cancer risk by estrogen and progesterone receptor status.
    Touillaud MS, Thiébaut AC, Fournier A, Niravong M, Boutron-Ruault MC, Clavel-Chapelon F.
    J Natl Cancer Inst; 2007 Mar 21; 99(6):475-86. PubMed ID: 17374837
    [Abstract] [Full Text] [Related]

  • 5. CYP17 5'-UTR MspA1 polymorphism and the risk of premenopausal breast cancer in a German population-based case-control study.
    Verla-Tebit E, Wang-Gohrke S, Chang-Claude J.
    Breast Cancer Res; 2005 Mar 21; 7(4):R455-64. PubMed ID: 15987450
    [Abstract] [Full Text] [Related]

  • 6. The association between dietary lignans, phytoestrogen-rich foods, and fiber intake and postmenopausal breast cancer risk: a German case-control study.
    Zaineddin AK, Buck K, Vrieling A, Heinz J, Flesch-Janys D, Linseisen J, Chang-Claude J.
    Nutr Cancer; 2012 Mar 21; 64(5):652-65. PubMed ID: 22591208
    [Abstract] [Full Text] [Related]

  • 7. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors.
    Ambrosone CB, Moysich KB, Furberg H, Freudenheim JL, Bowman ED, Ahmed S, Graham S, Vena JE, Shields PG.
    Breast Cancer Res; 2003 Mar 21; 5(2):R45-51. PubMed ID: 12631398
    [Abstract] [Full Text] [Related]

  • 8. Dietary phytoestrogen intake and premenopausal breast cancer risk in a German case-control study.
    Linseisen J, Piller R, Hermann S, Chang-Claude J, German Case-Control Study.
    Int J Cancer; 2004 Jun 10; 110(2):284-90. PubMed ID: 15069695
    [Abstract] [Full Text] [Related]

  • 9. The relationship between a polymorphism in CYP17 with plasma hormone levels and breast cancer.
    Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Kelsey KT, Hunter DJ.
    Cancer Res; 1999 Mar 01; 59(5):1015-20. PubMed ID: 10070957
    [Abstract] [Full Text] [Related]

  • 10. Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland.
    Pietinen P, Stumpf K, Männistö S, Kataja V, Uusitupa M, Adlercreutz H.
    Cancer Epidemiol Biomarkers Prev; 2001 Apr 01; 10(4):339-44. PubMed ID: 11319174
    [Abstract] [Full Text] [Related]

  • 11. Plasma enterolactone and genistein and the risk of premenopausal breast cancer.
    Piller R, Chang-Claude J, Linseisen J.
    Eur J Cancer Prev; 2006 Jun 01; 15(3):225-32. PubMed ID: 16679865
    [Abstract] [Full Text] [Related]

  • 12. Genetic polymorphism of CYP17 and breast cancer risk in Korean women.
    Shin MH, Lee KM, Yang JH, Nam SJ, Kim JW, Yoo KY, Park SK, Noh DY, Ahn SH, Kim B, Kang D.
    Exp Mol Med; 2005 Feb 28; 37(1):11-7. PubMed ID: 15761247
    [Abstract] [Full Text] [Related]

  • 13. Case-control study of phyto-oestrogens and breast cancer.
    Ingram D, Sanders K, Kolybaba M, Lopez D.
    Lancet; 1997 Oct 04; 350(9083):990-4. PubMed ID: 9329514
    [Abstract] [Full Text] [Related]

  • 14. Urinary phytoestrogens and postmenopausal breast cancer risk.
    den Tonkelaar I, Keinan-Boker L, Veer PV, Arts CJ, Adlercreutz H, Thijssen JH, Peeters PH.
    Cancer Epidemiol Biomarkers Prev; 2001 Mar 04; 10(3):223-8. PubMed ID: 11303591
    [Abstract] [Full Text] [Related]

  • 15. CYP17 genetic polymorphism, breast cancer, and breast cancer risk factors: Australian Breast Cancer Family Study.
    Chang JH, Gertig DM, Chen X, Dite GS, Jenkins MA, Milne RL, Southey MC, McCredie MR, Giles GG, Chenevix-Trench G, Hopper JL, Spurdle AB.
    Breast Cancer Res; 2005 Mar 04; 7(4):R513-21. PubMed ID: 15987458
    [Abstract] [Full Text] [Related]

  • 16. Role of dietary lignans in the reduction of breast cancer risk.
    Saarinen NM, Wärri A, Airio M, Smeds A, Mäkelä S.
    Mol Nutr Food Res; 2007 Jul 04; 51(7):857-66. PubMed ID: 17576639
    [Abstract] [Full Text] [Related]

  • 17. Dietary lignan intakes and risk of breast cancer by tumor estrogen receptor status.
    McCann SE, Kulkarni S, Trevisan M, Vito D, Nie J, Edge SB, Muti P, Freudenheim JL.
    Breast Cancer Res Treat; 2006 Oct 04; 99(3):309-11. PubMed ID: 16541305
    [Abstract] [Full Text] [Related]

  • 18. Serum enterolactone concentration is not associated with breast cancer risk in a nested case-control study.
    Kilkkinen A, Virtamo J, Vartiainen E, Sankila R, Virtanen MJ, Adlercreutz H, Pietinen P.
    Int J Cancer; 2004 Jan 10; 108(2):277-80. PubMed ID: 14639615
    [Abstract] [Full Text] [Related]

  • 19. The CYP17 MspA1 polymorphism and breast cancer risk: a meta-analysis.
    Ye Z, Parry JM.
    Mutagenesis; 2002 Mar 10; 17(2):119-26. PubMed ID: 11880540
    [Abstract] [Full Text] [Related]

  • 20. Plasma enterolactone and breast cancer risk in the Nurses' Health Study II.
    Xie J, Tworoger SS, Franke AA, Terry KL, Rice MS, Rosner BA, Willett WC, Hankinson SE, Eliassen AH.
    Breast Cancer Res Treat; 2013 Jun 10; 139(3):801-9. PubMed ID: 23760859
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.